COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 17 11 2020
medline: 5 1 2021
entrez: 16 11 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is associated with derangement in biomarkers of coagulation and endothelial function and has been likened to the coagulopathy of sepsis. However, clinical laboratory metrics suggest key differences in these pathologies. We sought to determine whether plasma coagulation and fibrinolytic potential in patients with COVID-19 differ compared with healthy donors and critically ill patients with sepsis. Approach and Results: We performed comparative studies on plasmas from a single-center, cross-sectional observational study of 99 hospitalized patients (46 with COVID-19 and 53 with sepsis) and 18 healthy donors. We measured biomarkers of endogenous coagulation and fibrinolytic activity by immunoassays, thrombin, and plasmin generation potential by fluorescence and fibrin formation and lysis by turbidity. Compared with healthy donors, patients with COVID-19 or sepsis both had elevated fibrinogen, d-dimer, soluble TM (thrombomodulin), and plasmin-antiplasmin complexes. Patients with COVID-19 had increased thrombin generation potential despite prophylactic anticoagulation, whereas patients with sepsis did not. Plasma from patients with COVID-19 also had increased endogenous plasmin potential, whereas patients with sepsis showed delayed plasmin generation. The collective perturbations in plasma thrombin and plasmin generation permitted enhanced fibrin formation in both COVID-19 and sepsis. Unexpectedly, the lag times to thrombin, plasmin, and fibrin formation were prolonged with increased disease severity in COVID-19, suggesting a loss of coagulation-initiating mechanisms accompanies severe COVID-19. Both COVID-19 and sepsis are associated with endogenous activation of coagulation and fibrinolysis, but these diseases differently impact plasma procoagulant and fibrinolytic potential. Dysregulation of procoagulant and fibrinolytic pathways may uniquely contribute to the pathophysiology of COVID-19 and sepsis.

Identifiants

pubmed: 33196292
doi: 10.1161/ATVBAHA.120.315338
pmc: PMC7942774
mid: NIHMS1669609
doi:

Substances chimiques

Biomarkers 0
Fibrinolysin EC 3.4.21.7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-414

Subventions

Organisme : NINDS NIH HHS
ID : U24 NS107228
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG059877
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130541
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD093826
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL069768
Pays : United States
Organisme : CSRD VA
ID : I01 CX001696
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126974
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141291
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG059892
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG048022
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142804
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL143403
Pays : United States

Références

Ann Intensive Care. 2019 Jan 30;9(1):19
pubmed: 30701381
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Clin Lab. 2019 Sep 1;65(9):
pubmed: 31532089
J Thromb Haemost. 2020 Nov;18(11):3121-3124
pubmed: 32790951
Blood. 2011 May 5;117(18):4953-63
pubmed: 21355090
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
J Trauma. 2001 May;50(5):801-9
pubmed: 11371835
J Thromb Haemost. 2020 Oct;18(10):2646-2653
pubmed: 32762118
J Thromb Haemost. 2020 Sep;18(9):2358-2363
pubmed: 32633068
Blood. 2009 Feb 5;113(6):1358-64
pubmed: 19056689
J Biol Chem. 1982 Mar 25;257(6):2912-9
pubmed: 7199524
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Crit Care Med. 2016 Jul;44(7):e574-8
pubmed: 26751613
Blood. 2004 Jun 15;103(12):4545-53
pubmed: 14988149
Blood. 2020 May 7;135(19):1704-1717
pubmed: 32315384
Lancet Haematol. 2020 Aug;7(8):e575-e582
pubmed: 32619411
Blood. 2014 Apr 24;123(17):2605-13
pubmed: 24632711
BMJ Open. 2020 Aug 11;10(8):e039849
pubmed: 32784264
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):367-71
pubmed: 23507662
Ann Hematol. 2020 Oct;99(10):2323-2328
pubmed: 32808105
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Science. 2004 Aug 27;305(5688):1283-6
pubmed: 15333838
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2020 Sep;18(9):2215-2219
pubmed: 32668058
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
JAMA. 2020 Aug 25;324(8):799-801
pubmed: 32702090
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2544-53
pubmed: 26494232
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Clin Chem Lab Med. 2020 Jun 25;58(7):1029-1036
pubmed: 32406381
Chest. 2015 Nov;148(5):1224-1230
pubmed: 26111103
Blood Rev. 2007 May;21(3):131-42
pubmed: 17208341
Intensive Care Med. 2003 Apr;29(4):530-8
pubmed: 12664219
Blood. 2020 Sep 10;136(11):1317-1329
pubmed: 32573711
EClinicalMedicine. 2020 Jun 25;24:100434
pubmed: 32766543
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Thromb Res. 2015 Jan;135(1):192-7
pubmed: 25467085
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2033-2044
pubmed: 32657623
Thromb Res. 2020 Jun;190:62
pubmed: 32305740
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712

Auteurs

Emma G Bouck (EG)

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill (E.G.B., L.A.H., A.S.W.).

Frederik Denorme (F)

University of Utah Molecular Medicine Program, Salt Lake City, UT (F.D., A.M.B., M.T.R., R.A.C.).

Lori A Holle (LA)

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill (E.G.B., L.A.H., A.S.W.).

Elizabeth A Middelton (EA)

Department of Internal Medicine (E.A.M., M.T.R., R.A.C.), University of Utah, Salt Lake City.

Antoinette M Blair (AM)

University of Utah Molecular Medicine Program, Salt Lake City, UT (F.D., A.M.B., M.T.R., R.A.C.).

Bas de Laat (B)

Synapse Research Institute, Maastricht, the Netherlands (B.d.L.).

Joshua D Schiffman (JD)

Department of Pediatrics (J.D.S., C.C.Y.), University of Utah, Salt Lake City.
PEEL Therapeutics, Inc, Salt Lake City, UT (J.D.S.).

Christian Con Yost (CC)

Department of Pediatrics (J.D.S., C.C.Y.), University of Utah, Salt Lake City.

Matthew T Rondina (MT)

University of Utah Molecular Medicine Program, Salt Lake City, UT (F.D., A.M.B., M.T.R., R.A.C.).
Department of Internal Medicine (E.A.M., M.T.R., R.A.C.), University of Utah, Salt Lake City.
George E. Wahlen VAMC Department of Internal Medicine and GRECC, Salt Lake City, UT (M.T.R.).

Alisa S Wolberg (AS)

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill (E.G.B., L.A.H., A.S.W.).

Robert A Campbell (RA)

University of Utah Molecular Medicine Program, Salt Lake City, UT (F.D., A.M.B., M.T.R., R.A.C.).
Department of Internal Medicine (E.A.M., M.T.R., R.A.C.), University of Utah, Salt Lake City.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH